The FDA today approved a new therapy for early Alzheimer’s disease that appears to modestly slow the progression of the disease that affects more than 6.5 million Americans.
July 6, 2023 –
The drug was granted accelerated approval in January, which allows the FDA to approve drugs for conditions when there is a defined need. It is the first therapy for Alzheimer’s granted full agency approval in 20 years. The FDA said the drug"demonstrated a statistically significant and clinically meaningful" reduction in decline from the disease. There are risks of brain bleeding and swelling, which sometimes can be fatal, the agency said.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA Approves Promising New Alzheimer’s Drug LeqembiNot only is it the first Alzheimer’s antibody treatment to get full FDA approval, it’s also the first that will be broadly covered by Medicare.
Leer más »
FDA Approves New Drug to Slow Alzheimer's DiseaseThe FDA today approved a new therapy for early Alzheimer's disease that appears to modestly slow the progression of the disease that affects more than 6.5 million Americans.
Leer más »
FDA approves use of Leqembi to treat Alzheimer's patientsFDA approves use of Leqembi Alzheimer\u0027s patients
Leer más »
FDA Approves First Leadless Dual-Chamber Pacing SystemThe FDA has approved 'the world's first' leadless dual-chamber pacing system, one based in part on an already-approved leadless single-chamber device. MedicalNews CardioTwitter
Leer más »
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Leer más »
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
Leer más »